Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors

International Journal of Laboratory Hematology

Volumn 33, Issue 3, 2011, Pages 326-331

  Ma, W ^a   Giles, F ^b   Zhang, X ^a   Wang, X ^a   Zhang, Z ^a   Lee, T S ^c   Yeh, C H ^a   Albitar, M ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c University of Minnesota   (United States)

Author keywords

Alternative splicing; BCR ABL1; Chronic myelogenous leukemia; Mutation; Resistance

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; DASATINIB; IMATINIB; NILOTINIB; NUCLEOTIDE; PROTEIN TYROSINE KINASE INHIBITOR; RNA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; EXON; FRAMESHIFT MUTATION; GENE INSERTION; GENE SEQUENCE; GENETIC SCREENING; GENETIC TRANSCRIPTION; HUMAN; INTRON; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; BASE SEQUENCE; DRUG RESISTANCE, NEOPLASM; EXONS; FUSION PROTEINS, BCR-ABL; HUMANS; INTRONS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN KINASE INHIBITORS; SEQUENCE ALIGNMENT;

EID: 79954769467     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2010.01291.x     Document Type: Article

References (16)

1. Borrow J. (2007) Guidelines for Mutation Analysis of BCR/ABL Kinase Domain: Interpreting TKI-Resistance Mutations in CML Patients. West Midlands Regional Genetics Laboratory, Birmingham.
2. Buratti E. & Baralle F.E. (2004) Influence of RNA secondary structure on the pre-mRNA splicing process. Molecular and Cellular Biology 24, 10505-10514.
3. Caceres J.F. & Kornblihtt A.R. (2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends in Genetics, 18, 186-193.
4. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N. & Sawyers C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.
5. Laudadio J., Deininger M.W., Mauro M.J., Druker B.J. & Press R.D. (2008) An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. The Journal of Molecular Diagnostics, 10, 177-180.
6. Lee T.-S., Ma W., Zhang X., Giles F., Cortes J., Kantarjian H. & Albitar M. (2008) BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Molecular Cancer Therapeutics, 7, 3834-3841.
7. Ma W., Kantarjian H., Yeh C.H., Zhang Z.J., Cortes J. & Albitar M. (2009) BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors. Acta Haematolology, 121, 27-31.
8. Modrek B. & Lee C. (2002) A genomic view of alternative splicing. Nature Genetics 30, 13-19.
9. Pajares M.J., Ezponda T., Catena R., Calvo A., Pio R. & Montuenga L.M. (2007) Alternative splicing: an emerging topic in molecular and clinical oncology. The Lancet Oncology 8, 349-357.
10. Salesse S., Dylla S.J. & Verfaillie C.M. (2004) p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells. Leukemia, 18, 727-733.
11. Stamm S., Ben-Ari S., Rafalska I., Tang Y., Zhang Z., Toiber D., Thanaraj T.A. & Soreq H. (2005) Function of alternative splicing. Gene 344, 1-20.
12. Stoilov P., Meshorer E., Gencheva M., Glick D., Soreq H. & Stamm S. (2002) Defects in Pre-mRNA Processing as Causes of and Predisposition to Diseases. DNA and Cell Biology, 21, 803-818.
13. Volpe G., Cignetti A., Panuzzo C., Kuka M., Vitaggio K., Brancaccio M., Perrone G., Rinaldi M., Prato G., Fava M., Geuna M., Pautasso M., Casnici C., Signori E., Tonon G., Tarone G., Marelli O., Fazio V.M. & Saglio G. (2007) Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Cancer Research 67, 5300-5307.
14. Wang Z., Xiao X., Van Nostrand E. & Burge C.B. (2006) General and specific functions of exonic splicing silencers in splicing control. Molecular Cell 23, 61-70.
15. Wong S. & Witte O.N. (2004) The BCR-ABL story: bench to bedside and back. Annual Review of Immunology, 22, 247-306.
16. Wu J.Y., Havlioglu N. & Yuan L. (2004) Alternatively spliced genes. In: Encyclopedia of Molecular Cell Biology and Molecular Medicine, Volume 1. (ed. R.A. Meyers ), 2nd edn, 125-177. Wiley-VCH, New York.